Consolidated Statement Of Cash Flows

AFC-HD AMS Life Science Co.,Ltd. - Filing #7341214

Concept As at
2024-02-29
2023-09-01 to
2024-02-29
As at
2023-08-31
As at
2023-02-28
2022-09-01 to
2023-02-28
As at
2022-08-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
92,280,000 JPY
446,612,000 JPY
Interest and dividends received
5,210,000 JPY
7,902,000 JPY
Interest paid
-39,567,000 JPY
-28,271,000 JPY
Income taxes paid
-322,770,000 JPY
-63,988,000 JPY
Net cash provided by (used in) operating activities
-264,847,000 JPY
397,356,000 JPY
Cash flows from investing activities
Purchase of investment securities
-418,633,000 JPY
-262,357,000 JPY
Net cash provided by (used in) investing activities
-1,354,435,000 JPY
-791,130,000 JPY
Proceeds from sale of investment securities
537,622,000 JPY
281,773,000 JPY
Other, net
63,893,000 JPY
-7,578,000 JPY
Cash flows from financing activities
Dividends paid
-208,898,000 JPY
-209,886,000 JPY
Proceeds from long-term borrowings
643,000,000 JPY
72,510,000 JPY
Repayments of long-term borrowings
-308,318,000 JPY
-91,028,000 JPY
Net cash provided by (used in) financing activities
707,537,000 JPY
923,657,000 JPY
Other, net
59,288,000 JPY
-25,579,000 JPY
Effect of exchange rate change on cash and cash equivalents
4,095,000 JPY
-1,883,000 JPY
Net increase (decrease) in cash and cash equivalents
-907,650,000 JPY
527,999,000 JPY
Cash and cash equivalents
10,154,370,000 JPY
11,062,021,000 JPY
10,785,778,000 JPY
10,257,778,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.